Quantcast

Latest Tumor suppressor genes Stories

Mutation Increases Melanoma Risk In Redheads
2013-08-23 04:22:04

April Flowers for redOrbit.com - Your Universe Online A person’s hair color and skin tone is determined by their skin pigment. This pigment is influenced by the melanocortin-1 (MC1R) gene receptor. For the world’s redheads – one to two percent of the population – their coloration is accounted for by a mutation in MC1R. A team of researchers led by Beth Israel Deaconess Medical Center (BIDMC) and Boston University School of Medicine (BUSM) has revealed that the same MC1R mutation...

2013-08-08 09:19:31

The global study was led by University of Melbourne and the Peter MacCallum Cancer Centre and published in the Journal of Clinical Oncology today. The study involved about 2,500 women from Europe, North America and Australia who have inherited mutations in BRCA1 or BRCA2, the breast cancer susceptibility genes, and who had been diagnosed with breast cancer. About one-third of these women were placed on tamoxifen. Tamoxifen has been used for decades to treat breast cancer and has...

2013-07-26 11:44:47

Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual's genetics. The research, published online today in Science, "increases understanding of the molecular mechanisms of action of PTEN, which is known to be defective in as many as half of all advanced...

2013-07-09 21:18:34

Discovery promises new targets for cancer drug design Genetic mutations aren’t the only thing that can keep a protein called PTEN from doing its tumor-suppressing job. Johns Hopkins researchers have now discovered that four small chemical tags attached (reversibly) to the protein’s tail can have the same effect, and they say their finding may offer a novel path for drug design to keep PTEN working. In a report published on July 9 in the journal...

2013-06-18 19:23:17

CNIO researchers take part in an international project that describes the molecular bases of resistance to a new chemotherapeutic agent in familial breast and ovarian cancers It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumors are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In patients with these mutations, PARP inhibitors, which are currently in clinical trials, have shown...

2013-06-14 23:15:49

Fulgent Therapeutics, a CLIA Certified Laboratory, announces today the inclusion of BRCA1 and BRCA2 analysis into its Hereditary Cancer Panel. Temple City, CA (PRWEB) June 14, 2013 Fulgent Therapeutics LLC, a CLIA Certified Laboratory, announces the inclusion of BRCA1 and BRCA2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets, making it the most comprehensive test for cancer risk assessment available. Fulgent Therapeutics Hereditary Cancer...

2013-06-13 23:03:37

Plaintiffs, including the American Civil Liberties Union, Association for Molecular Pathology, and American Society for Clinical Pathology, win long-fought case against Myriad Genetics, Association for Molecular Pathology v. Myriad Genetics, Inc. No. 12—398, that has far-reaching possibilities for genetic research and improved patient outcomes. Chicago, IL (PRWEB) June 13, 2013 The U.S. Supreme Court today invalidated patents on two genes associated with hereditary breast and ovarian...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'